China
Africa
Explore chapters and articles related to this topic
Antihistamines, Decongestants, and Expectorants during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Clemastine is a mast cell inhibitor and an H2 antihistamine. The frequency of congenital anomalies was not increased among 2847 infants whose mothers took clemastine during organogenesis (Gilbert et al., 2005). Among 7115 infants in the Swedish registry exposed to clemastine during the first trimester, the frequency of birth defects was not increased (Kallen, 2019).
Monographs of fragrance chemicals and extracts that have caused contact allergy / allergic contact dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Among the components of MP tested in 5 individuals, cinnamal caused 4 urticarial reactions, cinnamic acid 3, benzoic acid 3 and benzaldehyde 1. In seven patients repeat testing was performed. In five cases the urticarial reaction could be reproduced after a duration of 3–12 months. Oral provocation with 25 mg MP and 25 mg cinnamic acid failed to precipitate urticaria or other skin changes in four patients with urticaria and in one with allergic contact dermatitis. Passive transfer with serum from two patients to eight normal volunteers was negative. The urticarial reactions were diminished but not always inhibited by pre-treatment with oral antihistamines (clemastine 2 mg) (155).
Taxines
Published in Dongyou Liu, Handbook of Foodborne Diseases, 2018
In a separate report, a 42-year-old breast cancer sufferer with known T. baccata allergy (developing dyspnea and pruritus when passing yew trees) experienced dyspnea, pain in the chest and back, and tachycardia of 102 beats/min after docetaxel administration of 120 mg in 250 mL saline solution. Cessation of docetaxel and intravenous administration of clemastine 2 mg led to a quick disappearance of symptoms and return of normal heart rate. With a subsequent, stepwise acceleration in the docetaxel infusion rate and standard dexamethasone premedication, the patient completed treatment without any major side effects [18].
Clinical implications of myelin regeneration in the central nervous system
Published in Expert Review of Neurotherapeutics, 2018
Christopher E McMurran, Srikirti Kodali, Adam Young, Robin JM Franklin
To further interrogate OPC-modulating compounds, more functional assays have been developed. These include the micropillar array [78], in which mature oligodendrocytes wrap conical pillars with concentric rings of myelin. This assay led to clemastine, a drug with both anti-muscarinic and antihistamine properties approved primarily for symptomatic treatment of allergies. It has been shown to promote remyelination in vivo after lysolecithin-induced demyelination [79]. Experiments suggest clemastine has this effect by inhibiting the M1 muscarinic receptor, and oligodendroglial-specific genetic ablation of M1 receptors showed accelerated remyelination and functional recovery in EAE [79]. Clemastine is also in a Phase II clinical trial for use in MS (ClinicalTrials.gov Identifier: NCT02040298), from which preliminary results have shown an increase in the measured optic nerve conduction, but without a significant improvement in vision [80].
Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival
Published in Acta Oncologica, 2020
Ildikó Fritz, Philippe Wagner, Per Broberg, Rickard Einefors, Håkan Olsson
No overall survival benefit was seen when antihistamine users were grouped together, likely due to the fact that clemastine and cetirizine, two of the most commonly used H1-antihistamines, may negatively influence survival, counteracting the any potentially positive effects of desloratadine, ebastine and loratadine. We recommend that studies assessing risks and prognoses associated with antihistamine use should analyze the different drugs separately, as any combined effect may very well be negligible. This is supported by our study on survival in melanoma [2] and the Danish studies on survival in lung and ovarian cancer where these cationic amphiphilic antihistamines (a group to which clemastine, desloratadine, ebastine and loratadine belong) are associated with improved survival, but cetirizine and fexofenadine are not [4,5]. As clemastine is sometimes prescribed to counteract side effects of chemotherapy [4], our findings regarding its potentially detrimental effect on survival may be artefactual. To address this possible bias, we analyzed both peri-diagnostic and post-diagnostic use, as well as introduced lag time into the cumulative post-diagnostic analysis, excluding the time period adjacent to death, which would be most affected by any prescription bias for clemastine for terminal patients. Based on the lag-time analyses, we believe that the association with improved survival of desloratadine and loratadine is not artefactual, however, we cannot here draw the same conclusions regarding the possibly negative effects of clemastine and cetirizine, and the cationic amphiphilic properties of desloratadine, loratadine and ebastine may explain some of their potential effect.